Last updated: September 9, 2026
ONMEL, Merz Pharmaceuticals’ 200 mg itraconazole tablet for toenail onychomycosis, had a narrow commercial opportunity and limited public financial disclosure. The product entered a crowded antifungal market dominated by generic terbinafine, generic itraconazole capsules, and newer topical products. FDA records identify ONMEL’s NDA as discontinued for marketing, and Merz has not reported product-level revenue, prescription volume, or profitability. ONMEL’s commercial trajectory therefore is best characterized as a limited-launch, low-transparency product that did not develop into a material disclosed revenue asset.
What is ONMEL and what was its FDA regulatory status?
ONMEL is a 200 mg oral itraconazole tablet approved by the FDA for the treatment of toenail onychomycosis caused by dermatophytes. The product is distinct from Sporanox itraconazole capsules and oral solution because it uses a different tablet formulation and dosing regimen.
| Attribute |
ONMEL |
| Active ingredient |
Itraconazole |
| Dosage form |
200 mg tablet |
| Original sponsor |
Merz Pharmaceuticals, LLC |
| FDA application |
NDA 022484 |
| Approval date |
June 17, 2010 |
| Approved indication |
Toenail onychomycosis caused by dermatophytes |
| Regimen |
200 mg once daily for 12 weeks |
| Therapeutic class |
Triazole antifungal |
| FDA regulatory status |
Approved product; FDA records identify the marketing status as discontinued |
| Biosimilar status |
Not applicable; ONMEL is a small-molecule drug |
ONMEL’s principal product proposition was once-daily dosing for 12 weeks, compared with dosing schedules associated with older itraconazole capsule regimens. The product was not a new active ingredient. Its value depended on formulation, dosing convenience, physician adoption, and payer coverage.
When did ONMEL lose exclusivity?
ONMEL’s regulatory exclusivity was limited because approval involved an existing active ingredient rather than a new molecular entity.
The FDA granted three years of marketing exclusivity associated with the new dosage form or formulation. That period would have run from the June 17, 2010 approval date to approximately June 17, 2013. The exclusivity did not provide the five-year protection available to a new chemical entity.
| Exclusivity category |
ONMEL position |
| New chemical entity exclusivity |
No |
| Three-year clinical-investigation exclusivity |
Applicable to the approved application, expiring approximately June 17, 2013 |
| Orphan-drug exclusivity |
No public indication |
| Pediatric exclusivity |
No public indication |
| Patent protection |
Depended on formulation and related patent claims, not on the active ingredient alone |
The expiration of regulatory exclusivity did not automatically create an AB-rated generic tablet. An ANDA applicant would still need a pharmaceutically equivalent product and would need to address any active Orange Book patents with a Paragraph IV certification or wait for patent expiry.
What patents protect ONMEL?
ONMEL’s potential protection was concentrated in formulation, dosage form, and treatment-method claims rather than composition-of-matter protection for itraconazole.
Itraconazole had been commercially available before ONMEL. Earlier Sporanox patents could not provide the same level of protection as a new-molecule patent for ONMEL. The commercial importance of any ONMEL patent therefore depended on whether its claims covered:
- The specific 200 mg tablet formulation.
- The use of the tablet for toenail onychomycosis.
- Pharmaceutical compositions that improved itraconazole dissolution or bioavailability.
- Manufacturing processes for producing the tablet.
- Dosing schedules or administration methods.
The Orange Book, rather than the product label alone, is the controlling source for determining which patents were formally listed against NDA 022484 at a given date. Publicly available sources do not establish a material, long-dated patent estate comparable with the patent portfolios of major branded oncology, immunology, or specialty drugs.
How strong was the ONMEL patent estate?
The estate appears commercially moderate to weak for four reasons.
First, itraconazole itself was off-patent. Second, the product was a reformulated oral dosage form rather than a new molecular entity. Third, formulation patents generally face design-around risk. Fourth, a competing company could potentially pursue a different itraconazole tablet composition or dosage approach.
The main legal barrier would have been a patent claim broad enough to cover an alternative itraconazole tablet, not merely the precise ONMEL manufacturing process. Narrow formulation claims would have reduced the risk of direct infringement but increased the risk of non-infringing design-around products.
What was ONMEL’s competitive position?
ONMEL competed in a market with low-cost oral therapy and growing topical competition.
| Competitor |
Product type |
Competitive effect |
| Generic terbinafine |
Oral tablet |
Strong price and efficacy competitor |
| Generic itraconazole capsules |
Oral capsule |
Same active ingredient at materially lower acquisition cost |
| Sporanox |
Branded itraconazole capsule and solution |
Established physician familiarity |
| Jublia |
Topical efinaconazole solution |
Avoided systemic azole safety and interaction concerns |
| Kerydin |
Topical tavaborole solution |
Alternative topical treatment |
| Penlac and generic ciclopirox |
Topical lacquer |
Low-cost topical alternative |
| Laser and procedural treatments |
Non-drug options |
Competing treatment channel, although evidence and reimbursement varied |
Generic terbinafine was the most important economic competitor. It was widely used, generally inexpensive, and familiar to dermatologists and podiatrists. ONMEL’s once-daily regimen did not eliminate concerns associated with systemic antifungal treatment, including hepatic risk, drug interactions, and treatment monitoring.
Generic itraconazole capsules also limited ONMEL’s pricing power. Although the formulations were not identical, prescribers could select a lower-cost itraconazole product when they considered the clinical differences insufficient to justify ONMEL’s price.
How did the FDA label affect ONMEL’s market potential?
The label limited the addressable market to toenail onychomycosis caused by dermatophytes. It did not create a broad systemic antifungal franchise.
The label included clinically important safety restrictions and warnings associated with itraconazole, including:
- Congestive heart failure concerns.
- Clinically important drug-drug interactions.
- Hepatotoxicity risk.
- Variable absorption and exposure considerations.
- Contraindications involving certain co-administered drugs and patient conditions.
These restrictions reduced the number of patients for whom a physician would view ONMEL as an uncomplicated first-line option. Topical products had lower systemic exposure, although they generally required longer treatment periods and could have lower cure rates.
The product’s commercial thesis therefore required physicians to value once-daily tablet dosing over the cost of generics and the lower systemic burden of topical therapies. That positioning was difficult to sustain without strong payer support.
Were there Paragraph IV challenges or ONMEL patent litigation?
No major, widely reported Paragraph IV litigation campaign or settlement involving ONMEL is established in the public record available for this analysis.
The absence of a prominent litigation record is consistent with the product’s limited commercial scale. Generic applicants may have had little incentive to incur the cost of challenging formulation patents if the branded market was small or if a non-infringing itraconazole formulation could be developed.
A Paragraph IV challenge would have required an ANDA applicant to certify that listed patents were invalid, unenforceable, or not infringed. A successful challenge could have produced an early generic launch. A non-infringing ANDA approach could have avoided direct patent litigation but would still have required FDA review of pharmaceutical equivalence and bioequivalence.
No material ONMEL settlement agreement is publicly documented in the principal sources used here.
What is the Orange Book status of ONMEL?
ONMEL was associated with FDA-approved NDA 022484. Orange Book status should be evaluated in three separate dimensions:
- Whether the NDA remains listed as approved or discontinued.
- Whether any patents are currently listed against the NDA.
- Whether an ANDA is approved with an AB rating to the ONMEL tablet.
The existence of generic itraconazole capsules does not establish substitutability for ONMEL tablets. Dosage form, strength, formulation, and reference-product designation matter. A pharmacist generally cannot automatically substitute a capsule for a tablet solely because both contain itraconazole.
Because ONMEL’s FDA marketing status is discontinued, current commercial substitution and reimbursement questions are more important than the historical existence of the NDA. A discontinued branded product may leave a limited or nonexistent practical market even if residual patent rights remain.
What was ONMEL’s financial trajectory?
Public financial data do not provide a reliable standalone ONMEL revenue series. Merz is privately held and has not publicly disclosed a complete product-level revenue history for ONMEL. No defensible estimate of cumulative sales, peak sales, gross margin, or net present value can be derived from public filings alone.
The likely trajectory was shaped by the following factors:
| Period |
Market dynamic |
Financial implication |
| 2010 launch |
New once-daily itraconazole tablet entered an established antifungal market |
Required premium pricing and physician conversion |
| 2010-2013 |
Regulatory exclusivity period |
Limited direct generic tablet competition, but generic alternatives already existed |
| Post-2013 |
Loss of three-year exclusivity |
Increased vulnerability to formulation competition and payer pressure |
| Later commercial period |
Expansion of topical competitors and persistent generic pricing |
Reduced pricing power and likely lower prescription growth |
| Discontinuation period |
FDA records identified the product as discontinued |
Revenue contribution effectively ceased or became immaterial |
What drove ONMEL’s commercial underperformance?
The core issue was market substitution. ONMEL was not competing only against other branded tablets. It faced:
- Generic terbinafine at low cost.
- Generic itraconazole capsules containing the same active ingredient.
- Topical products promoted as safer or more convenient for selected patients.
- Procedural treatments marketed directly to consumers.
- Insurance formularies that often favored low-cost generic therapy.
A reformulated oral drug needs either substantial clinical differentiation or strong commercial execution. ONMEL’s once-daily dosing offered convenience, but public evidence does not show that the product created a sufficiently large clinical or economic advantage to overcome generic competition.
What generic launch risks exist for ONMEL?
The practical risk of generic erosion was higher than the risk of a classic immediate generic substitution event.
A competing manufacturer could pursue several routes:
- Develop an equivalent 200 mg itraconazole tablet.
- Challenge listed formulation patents under Paragraph IV.
- Wait for relevant patent expiry and file an ANDA.
- Market another itraconazole dosage form where legally and clinically appropriate.
- Compete indirectly through generic capsules rather than an exact tablet substitute.
The market risk was therefore broader than Orange Book substitution. Even if no AB-rated ONMEL generic launched, low-cost itraconazole capsules and terbinafine could erode demand.
Does ONMEL face biosimilar risk?
No. ONMEL is a small-molecule drug, so biosimilar pathways do not apply. Competitive entry would occur through the ANDA pathway or, depending on the product and formulation, another FDA small-molecule approval route.
The key competitive issues are pharmaceutical equivalence, bioequivalence, formulation patents, manufacturing cost, and reimbursement. Biologic interchangeability, reference-product exclusivity, and biosimilar substitution are not relevant to ONMEL.
What manufacturing and intellectual-property barriers affected ONMEL?
Itraconazole has formulation challenges involving dissolution and bioavailability. A tablet manufacturer would need to control:
- Particle size and solid-state properties.
- Excipients and dissolution performance.
- Content uniformity.
- Stability.
- Bioequivalence under FDA requirements.
- Commercial-scale manufacturing reproducibility.
These technical requirements can create an entry barrier, but they are not equivalent to a strong composition-of-matter patent. Competitors with formulation expertise could potentially develop alternative products that avoid narrow process or excipient claims.
Manufacturing complexity may have supported ONMEL’s initial differentiation, but it likely did not support durable premium pricing once physicians and payers had access to lower-cost alternatives.
How does ONMEL compare with Sporanox and generic itraconazole?
| Factor |
ONMEL |
Sporanox |
Generic itraconazole |
| Active ingredient |
Itraconazole |
Itraconazole |
Itraconazole |
| Main dosage form |
200 mg tablet |
Capsule and oral solution |
Mostly capsules |
| Brand position |
Once-daily tablet for toenail onychomycosis |
Established itraconazole brand |
Lowest-cost alternative |
| Patent strength |
Formulation and method claims |
Legacy formulation and product claims |
Usually no branded estate |
| Pricing power |
Limited |
Historically stronger brand recognition |
Low |
| Substitutability |
Not automatically interchangeable with capsules |
Not automatically interchangeable with all formulations |
Depends on dosage form and FDA reference status |
| Commercial outlook |
Discontinued marketing status |
Mature branded product |
Persistent generic competition |
ONMEL’s differentiation from generic itraconazole was real at the formulation level but limited at the therapeutic-class level. That distinction reduced its ability to maintain a durable market premium.
Key Takeaways
- ONMEL is a 200 mg itraconazole tablet approved in 2010 for toenail onychomycosis.
- FDA regulatory exclusivity was limited to approximately three years because itraconazole was not a new chemical entity.
- The product’s protection depended on formulation, method-of-use, and manufacturing claims rather than active-ingredient patents.
- Generic terbinafine, generic itraconazole capsules, and topical antifungals constrained pricing and adoption.
- No major public Paragraph IV litigation or ONMEL patent settlement is established.
- ONMEL has no biosimilar risk because it is a small-molecule drug.
- Merz has not publicly disclosed a standalone ONMEL revenue series.
- FDA records identify ONMEL’s marketing status as discontinued, indicating that current revenue exposure is likely immaterial.
- The product’s commercial decline was driven more by therapeutic substitution and weak differentiation than by a single documented generic launch event.
FAQs About ONMEL Market and Patent Status
Is ONMEL still marketed in the United States?
FDA records identify ONMEL as discontinued for marketing. Current availability may differ by wholesaler or residual inventory, but the product is not positioned as an active growth brand.
Is there a generic version of ONMEL 200 mg tablets?
Generic itraconazole capsules exist, but they are not automatically substitutable for ONMEL tablets. An exact generic tablet would require the applicable FDA approval and reference-product pathway.
Was ONMEL more effective than generic terbinafine?
ONMEL and terbinafine have different mechanisms, dosing, and safety profiles. Public product information does not establish a broad clinical superiority claim for ONMEL over terbinafine.
What company owned the ONMEL rights?
Merz Pharmaceuticals, LLC was the U.S. sponsor and commercial company associated with ONMEL’s FDA approval.
What was ONMEL’s peak annual revenue?
No verified public source discloses ONMEL’s peak annual revenue. Merz’s private-company reporting does not provide a reliable standalone product-level sales history.
References
-
U.S. Food and Drug Administration. (2010). ONMEL (itraconazole) tablets, prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ONMEL, NDA 022484. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
U.S. Food and Drug Administration. (2019). Approved drug products with therapeutic equivalence evaluations. FDA.
-
Merz Pharmaceuticals, LLC. (2010). ONMEL product information and prescribing information. Merz Pharmaceuticals.
